tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1108.070USD
+5.990+0.54%
Market hours ETQuotes delayed by 15 min
1.05TMarket Cap
39.29P/E TTM

TradingKey Stock Score of Eli Lilly and Co

Currency: USD Updated: 2026-06-22

Key Insights

Eli Lilly and Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1210.97.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eli Lilly and Co's Score

Industry at a Glance

Industry Ranking
20 / 157
Overall Ranking
72 / 4577
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

49°C

Very Low
Very High
Negative

Eli Lilly and Co Highlights

StrengthsRisks

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

High Growth
The company's revenue has grown steadily over the past 3 years, averaging 91.01% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.18B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 45.87%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 45.87%.
Undervalued
The company’s latest PE is 39.08, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 864.16M shares, increasing 7.39% quarter-over-quarter.
Held by Bernard Horn
Star Investor Bernard Horn holds 775.44K shares of this stock.

Analyst Rating

Based on 35 analysts
Buy
Current Rating
1210.975
Target Price
+10.23%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Eli Lilly and Co?

The TradingKey Stock Score provides a comprehensive assessment of Eli Lilly and Co based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Eli Lilly and Co’s performance and outlook.

How do we generate the financial health score of Eli Lilly and Co?

To generate the financial health score of Eli Lilly and Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Eli Lilly and Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Eli Lilly and Co.

How do we generate the company valuation score of Eli Lilly and Co?

To generate the company valuation score of Eli Lilly and Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Eli Lilly and Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Eli Lilly and Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Eli Lilly and Co.

How do we generate the earnings forecast score of Eli Lilly and Co?

To calculate the earnings forecast score of Eli Lilly and Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Eli Lilly and Co’s future.

How do we generate the price momentum score of Eli Lilly and Co?

When generating the price momentum score for Eli Lilly and Co, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Eli Lilly and Co’s prices. A higher score indicates a more stable short-term price trend for Eli Lilly and Co.

How do we generate the institutional confidence score of Eli Lilly and Co?

To generate the institutional confidence score of Eli Lilly and Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Eli Lilly and Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Eli Lilly and Co.

How do we generate the risk management score of Eli Lilly and Co?

To assess the risk management score of Eli Lilly and Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Eli Lilly and Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Eli Lilly and Co.
KeyAI